Because of these limitations, and because R-CHOP is now standard treatment for patients with DLBCL we increased the cohort to a total of 119 uniformly treated patients with additional follow-up time to investigate whether DAPK1 methylation can predict overall- and disease-specific survival in DLBCL. The gene discussed is DAPK1; the disease is diffuse large B-cell lymphoma.